Where to Buy Cytisine Powder？

Nicotine dependence is a major challenge to global public health - data from the World Health Organization show that 60% of smokers who quit smoke experience severe withdrawal symptoms in the first week, resulting in an annual relapse rate of over 80%. Faced with this stubborn pain point, the pharmaceutical industry is in urgent need of clinically proven solutions.

Cytisine, a natural alkaloid derived from the traditional Eastern European medicinal plant (Thermopsis lanceolata/Sophora alopecuroides), has been proven to be an effective smoking cessation active ingredient in more than 50 years of clinical applications due to its mechanism of action of selective binding to nicotine receptors. As a core raw material supplier in this field, KINTAIBIO^® produces 98% high-purity cytisine powder, which provides key formula raw materials for global smoking cessation product developers.

Thermopsis lanceolata

Sophora Alopecuroides

The smoking cessation efficacy of cytisine is based on rigorous scientific evidence: a study in the New England Journal of Medicine pointed out that its efficacy is comparable to that of varenicline, but the cost is only 1/10. Through innovative extraction technology, KINTAIBIO^® purifies 98% Sparteine powder that meets pharmaceutical standards. Its molecular structure is clear (CAS 485-35-8) , providing pharmaceutical companies with traceable and scalable core raw materials.

In response to the core needs of B-end customers for raw material purity, compliance and supply chain reliability, kINTAIBIO^® 98% cytisine powder has achieved:

• Compliance guarantee: GMP-certified production, COA, and related research reports
• Mass production capacity: annual production capacity ≥100kg, supporting seamless supply from clinical stage to commercialization
• Global applicability: in line with ICH stability guidelines (24 months at 40°C/RH75%)

This article will conduct an in-depth analysis of cytisine's mechanism of action, global market status, clinical data and key indicators of raw material procurement (purity, residual solvents, heavy metal limits, etc.), to help you efficiently develop a new generation of smoking cessation therapies. If you want to buy the raw material of 98% Sparteine powder directly, you can contact us at sales@kintaibio.com.

Our Sophora Alopecuroides Extract Cytisine powder (CAS 485-35-8) is a natural alkaloid extracted from the leguminous plant Sophora alopecuroides. As a partial agonist of the α4β2 nicotinic acetylcholine receptor (nAChR), it relieves withdrawal symptoms by activating the receptor at low intensity (agonism) and competitively blocks the binding of nicotine to the receptor (antagonism). This dual mechanism is different from the NRT therapy that only provides nicotine replacement.

Send Inquiry Details And Get A Free Sample And Get The Latest Price >>

KINTAIBIO^® 98% high-purity cytisine powder (HPLC determination) we provide can ensure:

• The difference between batches of receptor binding activity is ≤5%, ensuring the consistency of the dosage of the end product;
• The impurity content is <0.5%, meeting the control requirements of ICH Q3A for unknown impurities;
• The heavy metal residues (Pb/Cd/As/Hg) meet the USP<232> standard, reducing the complexity of the safety risk assessment of the end product.

Cytisine Powder, as an active ingredient for smoking cessation, has been used in mature products in many countries.This ingredient has supported mature smoking cessation brands in the Eastern European market for decades (such as Tabex^® and Desmoxan^®), serving more than 20 million smokers.

• Tabex^® (Bulgaria): Sopharma has been on the market since 1964, with a 25-day reduction regimen, covering the OTC market in Central and Eastern Europe.
• Desmoxan^® (Germany): Prescription preparation, using a decreasing dosage regimen similar to Tabex.
• Citizin^® (Russia): A localized brand, with dosage forms including tablets and solutions.

Note: The above brands are independently operated by third parties and are only examples of ingredient application, not commercial recommendations.

Key clinical evidence (supporting cytisine effectiveness)

• Traditional smoking cessation: The Cochrane systematic review (involving 8,000+ subjects) showed that the 6-month smoking cessation success rate of cytisine was significantly better than that of placebo (RR=3.98, 95%CI 2.01-7.87).
• E-cigarette cessation: ORCA-V1 Phase II trial (JAMA Internal Medicine, 2024): The cytisinicline group had a cessation rate of 32.1% vs. 15.0% in the placebo group (p=0.002).
• FDA regulatory breakthroughs and market opportunities in July 2024: Based on the ORCA-V1 data, the FDA granted cytisinicline for e-cigarette cessation, accelerating its approval process in the United States.
• Phase III trial progress:

Achieve Life Sciences has completed the ORCA-2/ORCA-3 trials (smoker indications), and the NDA was submitted in June 2025; ORCA-V2 (e-cigarette indications) Phase III is in progress.

Potential market growth:

If approved, the United States will become the world's first market to approve cytisinicline for dual cessation of e-cigarettes and traditional cigarettes, creating new incremental demand.

Purity and Consistency Industrial Assurance

Comprehensive Quality Compliance Documents

Basic Documents: COA provided for each batch (including HPLC spectrum, heavy metals, residual solvent data) and HPLC REPORT

Safety Reports: MSDS,TDS